Rob Sechan, Managing Partner, New Edge Capital

He added to it recently. Creative folks won't abandon Adobe's products; it's too embedded in workflows. Fundamentally, this was a great report: beat top and bottom, 11% revenue growth, 15% EPS growth, and net new annualized recurring revenue beat but fell short of forward forecast. Adobe will benefit from AI. You should consider buying this now.

Agrees with this call. Obesity drugs remain a big opportunity within healthcare, a $100-billion market by 2030, says Goldman; half the world's population would qualify by then. True, LLY is expensive at 55x forward PE, he still likes and owns this. He may trim at a higher price.

Also owns LLY and bought NVO for the same reasons: the obesity tailwind, but NVO is cheaper than LLY at 37x forward PE. This and LLY have 80-80% market share with tremendous growth and cash flow.

He just bought it. A play on the consumer and LULU's brand power. Offers consistent growth, leads returns on invested capital.  They report next week and he expects top and bottom line beats, and operational efficiencies. In contrast, Nike is a turnaround story. In a competitive industry and volatile consumer trends, but generates consistent 20% revenue growth over the last 10 years. Trades at a discount in terms of PE over the last 10 years.

Resilient profits and leveraged to rising manufacturing activity. Are one of the fastest-growing capital goods companies and boast terrific margins at 45%. Super positioning. Premium valuation but that's supported due to earnings momentum.

A defensive grower in the consumer space. Has taken some profits because its at all-time highs.

Bought it last week. A leading luxry brand with profits like a software company. Limited production fuels their pricing power and competitive advantage. Trades at 4x profitable of a carmaker and 2x the consumer discretionary sector.

In 2024, they will continue to execute, but will it be the best-performing tech stock? No. It may even lag peers. That said, MST is his biggest position and will hold on.

Nvidia has been the most exciting name in AI this year, but is up only 1% since late August, while AVGO has been up 23%. Invstors are looking beyond the obvious names and will continue to buy names like AVGO.

The sector is up 50% to date, but the revenue outlook is muddy due to the macro economy. So, he expects weaker demand for smartphones.

Sold it because of the slowing economy, and the company suffers from higher costs and lower volumes.

He sold Abbvie. He likes pharma, but this is a weaker name that's facing more competition.

He bought Comerica. Shares are down 30% this year, but recently it's breaking out. The regional banks are breaking out as a whole. The valuation is discounted at 7x PE 2024 and pays a 6.5% dividend yield. It's a larger regional in the healthy southern States and has less-than-average real estate exposure. Has healthy capital levels.

He added more shares of BABA today. It's an underrated grower at a reasonable price. It's a turnaround story reflecting the revival of the Chinese consumer. They dominant e-commerce in China, their cloud business is overlooked and cash flow yield is in the mid-teens. Trades at a 30% discount to its historic average.

Has long owned this. Got upgraded today. Pays a 3% dividend yield and trades at 15x forward PE. Healthcare will improve in 2024.